Eye Infections Treatment Market size was valued at USD 7.2 billion in 2021, growing at a CAGR of 3.6% from 2022-28. The global market provides a detailed overview and that can be segmented by type of infection, by medication, by Dosage form, and by distribution channel. By type of infection, the Eye Infections Treatment market growth has been segmented into Conjunctivitis, Blepharitis, Keratitis, Vitritis, Dry Eye, Chorioretinitis and Neuroretinitis. The Conjunctivitis segment is likely to be the largest and fastest-growing segment in terms of type of infection. The rise of this segment is mainly due to a rise in the prevalence of such infections. The segment is expected to witness growth in the forecast period due to the growing number of product launches to cure allergic conjunctivitis. It usually happens in people having seasonal allergies. Based on Medication, the Eye Infections Treatment market is segmented into Corticosteroids, Quinolone Antibiotics, Macrolide Antibiotics, Tetracycline Antibiotics, Polyene Antifungals, Aminoglycoside Antibiotics, and Others. Among these, the Tetracycline Antibiotics medication segment is expected to have a significantly growing market during the forecast period 2022-2028. Based on the Dosage form, the Eye Infections Treatment market is segmented into Gels and Cream, Eye drops, Tablets and Capsules. The Eye drops segment is expected to have a significant share in 2021. Based on the distribution channel, the Eye Infections Treatment market is segmented into Ophthalmology Clinics, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the surge in patient appointments to hospitals for regular eye check-ups and others issues. Besides, the online pharmacies segment is expected to arise as the fastest-growing segment in the eye infection treatment market share
In June 2021, Verkazia drug used for curing vernal keratoconjunctivitis in adults and children got US FDA approval which was developed by Santen Pharmaceutical Co., Ltd.
In February 2021, Eyevance Pharmaceuticals announced its partnership with Hikma Pharmaceuticals PLC for the promotion of ZERVIATE, which is used to treat ocular itching concerned with allergic conjunctivitis.